Shares of Amylyx Pharmaceuticals are down $16.22, or 85%, to $2.75 after the company announced that PHOENIX, a placebo-controlled Phase 3 clinical trial of AMX0035 in people living with amyotrophic lateral sclerosis, or ALS, did not meet its primary endpoint.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMLX:
- Amylyx Pharmaceuticals Assesses ALS Trial Setback and Future Steps
- 5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024
- Amylyx Pharmaceuticals, Inc.’s New Accounting & Financial Operations Risk – A Cause for Worry?
- Amylyx reports Q4 EPS 7c, consensus 23c
- SHAREHOLDER ALERT: Potential Recovery for Amylyx Pharmaceuticals, Inc. (AMLX) Investors
